A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

Bettina Proneth; Federico P. Portillo; Carrie Haskell-Luevano

doi:10.1007/978-0-387-73657-0_142

A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

Bettina Proneth, Federico P. Portillo, Carrie Haskell-Luevano

Medicinal Chemistry

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	319-320
Number of pages	2
Journal	Advances in experimental medicine and biology
Volume	611
DOIs	https://doi.org/10.1007/978-0-387-73657-0_142
State	Published - 2009

Bibliographical note

Funding Information:
The work was funded by the NIH RO1DK57080 grant.

Publisher link

10.1007/978-0-387-73657-0_142

Find It

Find It at U of M Libraries

Cite this

@article{9e4fd4047861434d94d8869909a63cb8,

title = "A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.",

author = "Bettina Proneth and Portillo, \{Federico P.\} and Carrie Haskell-Luevano",

note = "Funding Information: The work was funded by the NIH RO1DK57080 grant.",

year = "2009",

doi = "10.1007/978-0-387-73657-0\_142",

language = "English (US)",

volume = "611",

pages = "319--320",

journal = "Advances in experimental medicine and biology",

issn = "0065-2598",

publisher = "Springer",

}

TY - JOUR

T1 - A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

AU - Proneth, Bettina

AU - Portillo, Federico P.

AU - Haskell-Luevano, Carrie

N1 - Funding Information: The work was funded by the NIH RO1DK57080 grant.

PY - 2009

Y1 - 2009

UR - https://www.scopus.com/pages/publications/66349083291

UR - https://www.scopus.com/inward/citedby.url?scp=66349083291&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-73657-0_142

DO - 10.1007/978-0-387-73657-0_142

M3 - Article

C2 - 19400209

AN - SCOPUS:66349083291

SN - 0065-2598

VL - 611

SP - 319

EP - 320

JO - Advances in experimental medicine and biology

JF - Advances in experimental medicine and biology

ER -

A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

Bibliographical note

Publisher link

Find It

Other files and links

Cite this